Epilepsy is one of the most common neurological diseases in the world. International health institutions estimate that over 50 million people worldwide are affected by it. Seizures, the hallmark ...
For years, pharmaceutical companies have cut back on drug development that targeted neurological conditions. After trials and failures in dementia, depression, and epilepsy, companies learned that ...
NEW YORK--(BUSINESS WIRE)--Redpin Therapeutics, Inc., a pioneering chemogenetics company developing uniquely controllable gene therapies to address intractable diseases of the nervous system, today ...
Chemogenetics rescues the health of the molecular network (pink) that surrounds neurons (green) in laboratory models. Scientists used the technique to delay the onset of ALS symptoms. Disclaimer: AAAS ...
Redpin Therapeutics Inc., of New York, plans to take its newly secured $15.5 million series A financing to continue developing its ion-channel based chemogenetics platform for addressing neural ...
These results make it imperative for researchers to do proper controls with clozapine, and indicate that they should change their protocols altogether. “I’m glad I don’t own stock in CNO,” says Scott ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results